Press release
Bronchopulmonary Dysplasia Market to Witness Growth by 2032, Estimates DelveInsight | Key Companies - Oak Hill Bio, Chiesi Pharmaceutical, Medipost, Airway Therapeutics
Bronchopulmonary Dysplasia Market
Some of the key facts of the Bronchopulmonary Dysplasia Market Report:
https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
The market size of Bronchopulmonary Dysplasia was estimated to be USD 0.028 Million in the year 2021
Total incident cases of Bronchopulmonary Dysplasia in the 7MM were found to be approximately 17,058 cases in 2021
Among 7MM, the United States had the highest incident cases of Bronchopulmonary Dysplasia with approximately 13,222 cases in 2021
According to analysis, the severity‐specific data reveal the highest number of preterm infants have mild Bronchopulmonary Dysplasia, and Bronchopulmonary Dysplasia treatment should be initiated from then so
BPD is divided into three severity grades (mild, moderate,or severe) based on respiratory support needed at 28 weeks postmenstrual age (PMA).
Request a sample for the Bronchopulmonary Dysplasia Market Report: https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
Key benefits of the report:
Bronchopulmonary Dysplasia market report covers a descriptive overview and comprehensive insight of the Bronchopulmonary Dysplasia Epidemiology and Bronchopulmonary Dysplasia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Bronchopulmonary Dysplasia market report provides insights on the current and emerging therapies.
Bronchopulmonary Dysplasia market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Bronchopulmonary Dysplasia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Bronchopulmonary Dysplasia market.
Got queries? Click here to know more about the Bronchopulmonary Dysplasia Market Landscape https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
Bronchopulmonary Dysplasia Overview
According to National Organization for Rare Disorders (NORD), Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease that often occurs in low-weight or premature infants who have received supplemental oxygen or have spent long periods on a breathing machine (mechanical ventilation), such as infants with acute respiratory distress syndrome. BPD also occurs in older infants who experience abnormal lung development, an antenatal infection, placental abnormalities (like preeclampsia), or chorioamnionitis. Babies are not born with BPD, also referred to as chronic lung disease of prematurity; it is associated with how a baby's lung tissue develops.
The risk of developing BPD increases the earlier a baby is born and the lower the birth weight. Affected infants have rapid, labored breathing, tachypnea, cyanosis, feeding difficulties, and recurrent lung infection. Diagnosis is made based upon the identification of characteristic symptoms, detailed patient history, thorough clinical evaluation, and a variety of specialized tests, including blood tests, chest x-rays, and echocardiograms.
Bronchopulmonary Dysplasia Symptoms:
The symptoms of Bronchopulmonary Dysplasia include-
Rapid Breathing
Labored breathing
Wheezing
Difficulty in Feeding
Continuously getting affected with lung infections
Bluish discoloration around the mouth or lips
Epidemiology Segmentation of Astrocytoma:
Prevalent Cases of Astrocytoma in the 7MM [2019-2032]
Age-Specific Cases of Astrocytoma in the 7MM [2019-2032]
Gender-Specific Cases of Astrocytoma in the 7MM [2019-2032]
Diagnosed and Treated Cases of Astrocytoma in the 7MM [2019-2032]
Bronchopulmonary Dysplasia Market
The dynamics of the Bronchopulmonary Dysplasia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as AT-100, CHF5633, and others during the forecasted period 2019-2032.
Interested to know more about the Bronchopulmonary Dysplasia treatment and therapies, visit @ https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
Bronchopulmonary Dysplasia Pipeline Therapies:
OHB-607
AT-100
CHF5633
Pneumostem
Bronchopulmonary Dysplasia Pipeline Key Companies:
Oak Hill Bio
Chiesi Pharmaceutical
Medipost
Airway Therapeutics
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis of Bronchopulmonary Dysplasia Market
4. Bronchopulmonary Dysplasia Patient Share (%) Overview at a Glance
5. Bronchopulmonary Dysplasia Market Overview at a Glance
6. Bronchopulmonary Dysplasia Disease Background and Overview
7. Bronchopulmonary Dysplasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Bronchopulmonary Dysplasia
9. Bronchopulmonary Dysplasia Current Treatment and Medical Practices
10. Bronchopulmonary Dysplasia Unmet Needs
11. Bronchopulmonary Dysplasia Emerging Therapies
12. Bronchopulmonary Dysplasia Market Outlook
13. Country-Wise Bronchopulmonary Dysplasia Market Analysis (2018-2030)
14. Market Access and Reimbursement of Therapies
15. Bronchopulmonary Dysplasia Market drivers
16. Bronchopulmonary Dysplasia Market barriers
17. Appendix
18. Bronchopulmonary Dysplasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Bronchopulmonary Dysplasia Market Outlook 2032 https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Bronchopulmonary Dysplasia Epidemiology https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-epidemiology-forecast?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Bronchopulmonary Dysplasia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Bronchopulmonary Dysplasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=gpr
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence
https://www.delveinsight.com/consulting/competitive-intelligence-services
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchopulmonary Dysplasia Market to Witness Growth by 2032, Estimates DelveInsight | Key Companies - Oak Hill Bio, Chiesi Pharmaceutical, Medipost, Airway Therapeutics here
News-ID: 2688684 • Views: …
More Releases from DelveInsight Business Research
Peripheral T-Cell Lymphoma (PTCL) Market Analysis 2034 - Competitive Landscape, …
The Peripheral T-Cell Lymphoma (PTCL) Market across the 7MM was valued at approximately USD 680 million in 2020, and it is projected to experience steady growth by 2034.
Peripheral T-Cell Lymphoma (PTCL) Market Overview
As of 2023, the United States held the largest share of the PTCL therapeutics market within the 7MM, reaching a valuation of around USD 500 million, followed by Japan. Newly diagnosed patients are generally managed with anthracycline-based chemotherapy…
Nontuberculous Mycobacterial Infection Market Analysis 2034 - Competitive Landsc …
In 2023, the Nontuberculous Mycobacterial (NTM) Infections Market in the United States was valued at around USD 360 million, and it is projected to grow throughout the 2024-2034 forecast period.
Nontuberculous Mycobacterial Market Overview
The NTM infections market is anticipated to expand consistently between 2024 and 2034, fueled by advancements in diagnostics, the introduction of novel therapies, and growing disease awareness. The aging population, which is more susceptible to NTM infections, continues…
Lupus Nephritis Market Analysis 2034 - Competitive Landscape, Clinical Trials, M …
The Lupus Nephritis (LN) market was valued at approximately USD 1.8 billion in 2024 and is projected to expand steadily from 2025 to 2034, driven by the introduction of emerging therapies across the seven major markets (7MM).
Lupus Nephritis Market Summary
In Japan, the Lupus Nephritis market size was around USD 49 million in 2024, and it is anticipated to grow throughout the forecast period (2025-2034). Lupus Nephritis, a serious complication of…
Sjogren's Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medicatio …
Prominent Sjogren's syndrome companies include Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and several others.
Sjogren's Syndrome Market Summary
In 2023, the Sjogren's syndrome market size across the seven major markets (7MM) was valued at approximately USD 1.9 billion and is expected to witness steady growth through 2034.
Sjogren's syndrome is an autoimmune disease that primarily disrupts the salivary…
More Releases for Bronchopulmonary
Bronchopulmonary Dysplasia (BPD) Patient Pool Analysis and Market Forecast 2024- …
Introduction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily affects premature infants requiring prolonged mechanical ventilation or supplemental oxygen. It remains one of the most serious complications of preterm birth, with lasting effects on pulmonary function, growth, and neurodevelopment.
The condition not only drives neonatal intensive care unit (NICU) costs but also increases long-term healthcare utilization for affected children. Growing global rates of preterm birth, along with improvements in neonatal…
Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis
Bronchopulmonary Dysplasia (BPD) represents one of the most significant complications of preterm birth, affecting the respiratory system of premature infants and creating substantial healthcare challenges worldwide. The BPD epidemiology market encompasses therapeutic interventions, diagnostic tools, and supportive care technologies designed to address this chronic lung disease affecting neonates. As medical advances continue to improve survival rates among extremely premature infants, the prevalence of BPD has correspondingly increased, driving demand for…
Bronchopulmonary Dysplasia Treatment Market Growth Projections and Trends (2023- …
Bronchopulmonary Dysplasia (BPD) Treatment Market
Global Bronchopulmonary Dysplasia Treatment Market Overview
The global bronchopulmonary dysplasia (BPD) treatment market is poised for significant growth in the coming years. The market was valued at USD X billion in 2023 and is expected to reach USD Y billion by 2030, expanding at a CAGR of Z% from 2024 to 2030. With advancements in neonatal care and increasing awareness about BPD treatment options, the demand for…
Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment Report 2024 (Updated …
DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more…
Bronchopulmonary Dysplasia Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Bronchopulmonary Dysplasia Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
BDP Market Size And Scope
The global BDP (Butane Diol Propylene) market is witnessing steady growth, fueled by its diverse applications in industries such as…
Bronchopulmonary Dysplasia Market to Reach US$ 445.6 Million by 2034
Market Overview:
The bronchopulmonary dysplasia market reached a value of US$ 269.3 Million in 2023 and expected to reach US$ 445.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2024-2034.
The report offers a comprehensive analysis of the bronchopulmonary dysplasia market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market,…
